Gastroparesis, also known as delayed gastric emptying or stomach paralysis, is a disorder that slows or stops the digestive process and disrupts normal bowel movement activity. This chronic condition is commonly a complication related to diabetes, certain surgeries, and medications, such as GLP-1 agonists.

Symptoms include:

• Nausea and Vomiting
• Bloating
• Abdominal pain
• Feeling full after only a few bites of food
• Acid reflux
• Changes in blood sugar levels
• Lack of appetite
• Weight loss and malnutrition
• Overall impaired quality of life

Gastroparesis is associated with elevated levels of fasting and postprandial gastric inhibitory peptide (GIP), acute postprandial hyperglycemia, reduced intestinal transit time and higher rates of slow transit constipation.

In clinical studies Mizagliflozin has been shown to improve each of these disease characteristics by reducing postprandial GIP, lowering peak postprandial glucose and relieving constipation. Vogenx is preparing for initiation of a phase 2 randomized, parallel group, double-blind, placebo-controlled study comparing different doses of mizagliflozin on gastric emptying time in patients diagnosed with gastroparesis.